Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0.1% – Time to Sell?

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA)’s share price fell 0.1% during trading on Friday . The stock traded as low as $10.65 and last traded at $10.65. Approximately 4,565 shares traded hands during trading, a decline of 90% from the average daily volume of 46,969 shares. The stock had previously closed at $10.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition Stock Performance

The business has a 50 day moving average price of $10.61 and a 200-day moving average price of $10.51.

Drugs Made In America Acquisition (NASDAQ:DMAA) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.06 earnings per share for the quarter.

Hedge Funds Weigh In On Drugs Made In America Acquisition

A number of large investors have recently made changes to their positions in DMAA. Quarry LP acquired a new stake in shares of Drugs Made In America Acquisition in the third quarter valued at about $161,000. Sandia Investment Management LP acquired a new position in Drugs Made In America Acquisition during the third quarter worth about $161,000. Lineage Point Capital LP acquired a new position in Drugs Made In America Acquisition during the fourth quarter worth about $330,000. Shaolin Capital Management LLC purchased a new position in Drugs Made In America Acquisition in the second quarter valued at about $1,020,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter valued at approximately $1,024,000.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.